Venus Remedies Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 1:38 am

Market Cap	418 Cr.
Current Price	313
High / Low	430/280
Stock P/E	18.9
Book Value	370
Dividend Yield	0.00 %
ROCE	8.57 %
ROE	5.94 %
Face Value	10.0
PEG Ratio	-1.21

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for

Competitors of

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,354 Cr.	308	390/128	63.6	20.5	0.22 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	62.6 Cr.	84.4	94.9/26.6	24.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.9 Cr.	24.5	24.5/8.74	46.6	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	86.7 Cr.	115	155/87.0	13.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Glenmark Life Sciences Ltd	12,416 Cr.	1,013	1,335/645	29.3	207	2.22 %	28.1 %	21.1 %	2.00
Industry Average	19,016.52 Cr	1,181.31		56.05	186.30	0.32%	16.20%	16.32%	6.27

All Competitor Stocks of

Quarterly Result

Month	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Sales	111	130	203	124	142	143	140	117	156	95	168	143	195
Expenses	107	113	175	112	137	129	127	109	131	85	150	131	176
Operating Profit	4	17	27	12	6	15	13	8	25	10	18	12	19
OPM %	4%	13%	13%	10%	4%	10%	9%	7%	16%	11%	11%	8%	10%
Other Income	24	2	3	1	2	1	2	4	3	2	3	2	4
Interest	1	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	9	9	9	9	8	8	9	7	8	8	6	7	6
Profit before tax	18	10	21	5	0	8	6	5	20	5	14	8	17
Tax %	-93%	-17%	-8%	-20%	0%	13%	8%	28%	44%	77%	31%	12%	40%
Net Profit	35	12	23	6	0	7	5	3	11	1	10	7	11
EPS in Rs	28.45	8.75	17.32	4.23	0.17	5.15	3.99	2.46	8.27	0.88	7.44	5.12	7.86

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 3:17 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	459	531	455	407	400	372	322	335	544	597	552	596	615
Expenses	339	393	366	326	349	333	289	295	490	535	492	537	554
Operating Profit	120	138	89	81	51	39	33	41	54	62	60	60	61
OPM %	26%	26%	20%	20%	13%	11%	10%	12%	10%	10%	11%	10%	10%
Other Income	0	0	1	2	2	2	-3	-4	43	8	10	12	11
Interest	25	29	41	38	34	35	25	13	13	0	0	0	0
Depreciation	33	40	46	42	40	34	34	32	35	34	32	26	25
Profit before tax	63	69	3	4	-22	-28	-30	-8	49	36	38	45	46
Tax %	9%	7%	-95%	52%	-21%	11%	-4%	24%	-27%	-12%	30%	36%
Net Profit	57	64	5	2	-17	-31	-29	-10	62	41	27	28	29
EPS in Rs	54.36	56.20	4.51	1.49	-13.84	-24.87	-23.15	-8.10	50.05	30.46	19.88	21.31	21.33
Dividend Payout %	6%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	12.28%	-92.19%	-60.00%	-950.00%	-82.35%	6.45%	65.52%	720.00%	-33.87%	-34.15%	3.70%
Change in YoY Net Profit Growth (%)	0.00%	-104.47%	32.19%	-890.00%	867.65%	88.80%	59.07%	654.48%	-753.87%	-0.28%	37.85%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	1%
5 Years:	13%
3 Years:	3%
TTM:	15%

Compounded Profit Growth
10 Years:	-8%
5 Years:	28%
3 Years:	-10%
TTM:	-13%

Stock Price CAGR
10 Years:	4%
5 Years:	70%
3 Years:	-6%
1 Year:	-20%

Return on Equity
10 Years:	2%
5 Years:	6%
3 Years:	7%
Last Year:	6%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 2:29 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	11	11	11	11	12	12	12	12	12	13	13	13	13
Reserves	369	450	445	426	376	350	320	311	388	427	447	474	481
Borrowings	271	289	321	335	312	307	298	220	51	43	42	41	41
Other Liabilities	67	84	64	70	65	82	102	100	104	97	98	98	125
Total Liabilities	718	834	841	843	765	751	733	644	556	580	601	627	660
Fixed Assets	401	439	444	452	406	389	364	289	262	241	216	219	237
CWIP	48	68	78	80	66	65	65	25	25	25	26	21	23
Investments	0	0	0	0	0	0	0	0	0	0	20	19	56
Other Assets	268	327	319	310	293	297	304	330	269	314	339	368	345
Total Assets	718	834	841	843	765	751	733	644	556	580	601	627	660

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	52	53	68	47	59	31	45	78	132	41	37	37
Cash from Investing Activity +	-104	-95	-67	3	-18	8	-11	-5	57	-17	-58	-8
Cash from Financing Activity +	55	40	-1	-46	-44	-39	-35	-73	-162	-9	-1	-1
Net Cash Flow	3	-2	-1	3	-4	0	-1	-0	27	14	-22	28

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-151.00	-151.00	-232.00	-254.00	-261.00	-268.00	-265.00	-179.00	3.00	19.00	18.00	19.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	37	45	51	55	43	46	43	33	21	24	51	49
Inventory Days	178	173	194	219	226	246	286	296	129	118	132	125
Days Payable	26	38	40	38	48	52	72	77	76	47	56	45
Cash Conversion Cycle	190	180	204	236	221	240	257	252	74	95	127	129
Working Capital Days	98	115	146	179	163	144	127	166	74	85	112	120
ROCE %	15%	14%	6%	5%	2%	1%	1%	2%	8%	8%	8%	9%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	40.81%	40.81%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
FIIs	0.28%	0.33%	0.96%	1.13%	1.07%	1.00%	0.98%	1.03%	1.59%	1.48%	1.06%	1.18%
Public	58.91%	58.86%	57.28%	57.11%	57.19%	57.26%	57.26%	57.21%	56.65%	56.76%	57.17%	57.06%
No. of Shareholders	18,231	19,952	21,189	22,015	22,243	21,719	20,498	19,267	19,560	19,913	19,614	19,557

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	21.31	19.88	30.86	50.04	-8.10
Diluted EPS (Rs.)	21.31	19.88	30.86	50.04	-8.10
Cash EPS (Rs.)	41.08	44.04	55.55	78.63	17.84
Book Value[Excl.RevalReserv]/Share (Rs.)	364.66	344.38	329.50	324.33	262.01
Book Value[Incl.RevalReserv]/Share (Rs.)	364.66	344.38	329.50	324.33	262.01
Revenue From Operations / Share (Rs.)	449.85	415.58	447.86	444.11	274.94
PBDIT / Share (Rs.)	53.23	52.76	52.68	59.48	37.37
PBIT / Share (Rs.)	33.45	28.60	27.60	30.90	11.44
PBT / Share (Rs.)	33.39	28.38	27.24	39.34	-6.51
Net Profit / Share (Rs.)	21.31	19.87	30.47	50.04	-8.10
NP After MI And SOA / Share (Rs.)	21.31	19.87	30.47	50.04	-8.10
PBDIT Margin (%)	11.83	12.69	11.76	13.39	13.59
PBIT Margin (%)	7.43	6.88	6.16	6.95	4.15
PBT Margin (%)	7.42	6.82	6.08	8.85	-2.36
Net Profit Margin (%)	4.73	4.78	6.80	11.26	-2.94
NP After MI And SOA Margin (%)	4.73	4.78	6.80	11.26	-2.94
Return on Networth / Equity (%)	5.84	5.77	9.24	15.43	-3.09
Return on Capital Employeed (%)	8.17	7.37	7.57	8.31	3.36
Return On Assets (%)	4.54	4.41	7.02	11.11	-1.56
Long Term Debt / Equity (X)	0.07	0.08	0.08	0.11	0.22
Total Debt / Equity (X)	0.08	0.09	0.09	0.12	0.48
Asset Turnover Ratio (%)	0.97	0.90	1.01	0.86	0.46
Current Ratio (X)	4.53	3.91	3.00	2.38	1.32
Quick Ratio (X)	2.99	2.46	1.64	1.15	0.67
Inventory Turnover Ratio (X)	2.85	2.65	3.04	2.64	1.22
Interest Coverage Ratio (X)	790.78	239.55	146.41	5.64	3.46
Interest Coverage Ratio (Post Tax) (X)	317.56	91.24	85.67	3.94	0.91
Enterprise Value (Cr.)	409.63	205.06	351.82	361.07	183.27
EV / Net Operating Revenue (X)	0.68	0.36	0.58	0.65	0.54
EV / EBITDA (X)	5.76	2.91	5.00	4.92	3.97
MarketCap / Net Operating Revenue (X)	0.72	0.38	0.60	0.61	0.08
Price / BV (X)	0.89	0.47	0.81	0.84	0.08
Price / Net Operating Revenue (X)	0.72	0.38	0.60	0.61	0.08
EarningsYield	0.06	0.12	0.11	0.18	-0.36

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 423.69

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Undervalued by 35.36% compared to the current share price 313.00

Intrinsic Value of as of December 22, 2024 is: 357.24

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Undervalued by 14.13% compared to the current share price 313.00

Last 5 Year EPS CAGR: -15.68%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (404.92 cr) compared to borrowings (197.77 cr), indicating strong financial stability. The company has shown consistent growth in sales (475.77 cr) and profit (20.38 cr) over the years.	The stock has a low average ROCE of 6.58%, which may not be favorable. The stock has a high average Working Capital Days of 127.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 183.75, which may not be favorable.

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
1. Net Profit Margin: 4.73%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 8.17% (Industry Average ROCE: 16.07%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 5.84% (Industry Average ROE: 15.77%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 317.56
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.99
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 18.9 (Industry average Stock P/E: 46.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.08
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Venus Remedies Ltd. is a Public Limited Listed company incorporated on 15/09/1989 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1989PLC009705 and registration number is 009705. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 575.18 Cr. and Equity Capital is Rs. 13.37 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	S.C.O. 857, C. No. 10, 2nd Floor, NAC Manimajra, Chandigarh Chandigarh 160101	investorgrievance@venusremedies.com http://www.venusremedies.com

Management
Name	Position Held
Mr. Pawan Chaudhary	Chairman & Managing Director
Dr.(Mrs.) Manu Chaudhary	Joint Managing Director
Mr. Peeyush Jain	Deputy Managing Director
Mr. Ashutosh Jain	Executive Director
Mr. Akshansh Chaudhary	Executive Director
Dr.(Mrs.) Savita Gupta	Independent Director
Mr. N P S Monga	Independent Director
Mr. Navdeep Sud	Independent Director
Dr. Gilbert Wenzel	Independent Director
Dr. S K Chadha	Independent Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 22 December 2024 is ₹423.69, which is 35.36% higher than the current market price of ₹313.00. The stock has a market capitalization of 418 Cr. and recorded a high/low of 430/280 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹481 Cr and total liabilities of ₹660 Cr.

What is the Market Cap of ?

The Market Cap of is 418 Cr..

What is the current Stock Price of as on 22 December 2024?

The current stock price of as on 22 December 2024 is 313.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 430/280.

What is the Stock P/E of ?

The Stock P/E of is 18.9.

What is the Book Value of ?

The Book Value of is 370.

What is the Dividend Yield of ?

The Dividend Yield of is 0.00 %.

What is the ROCE of ?

The ROCE of is 8.57 %.

What is the ROE of ?

The ROE of is 5.94 %.

What is the Face Value of ?

The Face Value of is 10.0.